Menu
Search
|

Menu

Close
X

Savara Inc SVRA.OQ (NASDAQ Stock Exchange Global Select Market)

12.39 USD
-0.31 (-2.44%)
As of Feb 16
chart
Previous Close 12.70
Open 12.61
Volume 81,788
3m Avg Volume 53,583
Today’s High 12.61
Today’s Low 12.16
52 Week High 17.11
52 Week Low 4.63
Shares Outstanding (mil) 30.50
Market Capitalization (mil) 377.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.633
FY16
-6.540
FY15
-17.192
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
4,553.06
8.57
Price to Book (MRQ)
vs sector
4.05
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
20.41
15.12
LT Debt to Equity (MRQ)
vs sector
20.06
11.85
Return on Investment (TTM)
vs sector
-44.43
13.54
Return on Equity (TTM)
vs sector
-69.02
14.80

EXECUTIVE LEADERSHIP

Robert Neville
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Taneli Jouhikainen
President, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
David Lowrance
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Nevan Elam
Independent Director, Since 2017
Salary: --
Bonus: --
Richard Hawkins
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

900 S Capital of Texas Hwy Ste 1
WEST LAKE HILLS   TX   78746-5436

Phone: +1512.6141848

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SPONSORED STORIES